A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II) (SAFRON II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01965223|
Recruitment Status : Completed
First Posted : October 18, 2013
Last Update Posted : November 4, 2020
|Condition or disease||Intervention/treatment||Phase|
|Cancer Metastases to the Lung||Radiation: Multi-fraction SABR Radiation: Single Fraction SABR||Not Applicable|
Stereotactic Ablative Body Radiotherapy (SABR) is an exciting novel radiotherapy technique that is delivered over very few sessions. In the case of limited pulmonary 'oligometastases', SABR can result in long-term survival. It is non-invasive and associated with high rates of tumour control and relatively low toxicity. Additionally, the large doses of precision radiotherapy involved may evoke a strong immune response to recognise and attack any remaining tumour cells. In the future, SABR may be an attractive alternative to invasive surgery. There are two SABR techniques emerging in Australia; fractionated and single fraction treatments. We aim to conduct the first clinical trial of SABR in patients with limited pulmonary metastases testing fractionated versus single fraction treatments.
The primary aim of this study is to evaluate the toxicity, Quality of Life, clinical efficacy and cost effectiveness of single fraction SABR compared to multi-fraction SABR in patients with oligometastases to the lung.
The secondary aim of this study is to assess the immune response evoked by both fractionated and single fraction SABR and its prognostic implications for patient outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial|
|Actual Study Start Date :||February 4, 2015|
|Actual Primary Completion Date :||July 27, 2020|
|Actual Study Completion Date :||July 27, 2020|
Experimental: Multi-fraction SABR
Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
Radiation: Multi-fraction SABR
Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
Experimental: Single fraction SABR
Radiotherapy: 28Gy delivered in 1 fraction
Radiation: Single Fraction SABR
Single fraction SABR; 28Gy delivered in 1 fraction
- Toxicity [ Time Frame: 12 months ]The primary outcome is safety, defined as number of participants experiencing less than or equal to 5% toxicity at 12 months post treatment (toxicity as measured by CTCAE V4).
- Quality of Life [ Time Frame: 24 months ]To compare quality of life outcomes between techniques assessed using EQ-5DL and MDASI-LC questionnaires.
- Time to local failure [ Time Frame: 24 months ]Local progression free survival assesed by CT scan and clinical assessment
- Overall survival [ Time Frame: 24 months ]Overall survival assesed by clinical assessment
- Time to distant failure [ Time Frame: 24 months ]Time to distant failure assessed by CT scan and clinical assessment
- Resources use and costs associated with treatment [ Time Frame: 24 months ]Resources use and costs associated with treatment assessed by EQ5DL and accessing Medicare data
- Disease Free Survival [ Time Frame: 24 months ]Disease free survival will be measured from the date of randomisation to the date of a local recurrence, regional or distant metastasis, or death from any cause, whichever occurs first.
- Immune response [ Time Frame: 3 months ]To explore immune system responses to single fraction and multi-fraction SABR.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01965223
|Australia, New South Wales|
|Liverpool, New South Wales, Australia, 2170|
|Calvary Mater Hospital|
|Newcastle, New South Wales, Australia, 2298|
|Prince of Wales Hospital|
|Randwick, New South Wales, Australia, 2031|
|Northern Sydney Cancer Centre (RNS)|
|St Leonards, New South Wales, Australia, 2065|
|Sydney, New South Wales, Australia, 2560|
|Princess Alexandra Hospital|
|Woolloongabba, Queensland, Australia, 4102|
|Australia, South Australia|
|Royal Adelaide Hospital|
|Adelaide, South Australia, Australia, 5000|
|Peter MacCallum Cancer Center|
|Melbourne, Victoria, Australia, 3002|
|Australia, Western Australia|
|Sir Charles Gairdner Hospital|
|Nedlands, Western Australia, Australia, 6009|
|Study Chair:||Shankar Siva||Peter MacCallum Cancer Centre, Australia|